Fig. S6
- ID
- ZDB-FIG-170706-28
- Publication
- Pei et al., 2016 - Additive reductions in zebrafish PRPS1 activity result in a spectrum of deficiencies modeling several human PRPS1-associated diseases
- Other Figures
- All Figure Page
- Back to All Figure Page
Inhibition on pyrimidine synthesis by leflunomide partially phenocopies the prps1a:prps1b mutant phenotypes. (A) Leflunomide treatment of wild-type embryos leads to a dose-dependent reduction in melanocytes and eye size. Leflunomide concentrations are as labeled. Arrows point to small eye and melanocyte reduction in the embryo treated with 2 uM of leflunomide. (B) Dose-dependent reduction of retinal iridophores in leflunomide treated embryos. (C) Quantification of eye size reduction. Eye size is measured by Image J. A significant reduction in eye size is detected between leflunomide at 0 uM and1 uM (n=10, p<0.001), and between leflunomide at 1 uM and 2 uM (n=10, p<0.001). (D) Dose-dependent reduction of neuromast hair cells in leflunomide treated embryos. A significant reduction in neuromast hair cells is detected between leflunomide at 0 uM and 1 uM (n=9, p=0.03), and between leflunomide at 1 uM and 2 uM (n=9, p<0.001). Graphs show the mean and s. e. m.. The data shown were replicated in another independent experiment. |